Assembly Biosciences, Inc. (ASMB) Director William R. Ringo Sells 1,000 Shares
Assembly Biosciences, Inc. (NASDAQ:ASMB) Director William R. Ringo sold 1,000 shares of the firm’s stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $29.55, for a total transaction of $29,550.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Assembly Biosciences, Inc. (NASDAQ ASMB) traded up $1.67 during midday trading on Friday, reaching $30.25. 142,723 shares of the company’s stock traded hands, compared to its average volume of 110,692.
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. grew its position in Assembly Biosciences by 21.2% in the 2nd quarter. Vanguard Group Inc. now owns 610,916 shares of the biopharmaceutical company’s stock worth $12,615,000 after purchasing an additional 107,065 shares during the last quarter. State Street Corp acquired a new stake in shares of Assembly Biosciences during the 2nd quarter valued at about $4,234,000. Northern Trust Corp boosted its position in shares of Assembly Biosciences by 221.2% during the 2nd quarter. Northern Trust Corp now owns 195,321 shares of the biopharmaceutical company’s stock valued at $4,033,000 after acquiring an additional 134,513 shares in the last quarter. JPMorgan Chase & Co. acquired a new stake in shares of Assembly Biosciences during the 2nd quarter valued at about $3,426,000. Finally, Lyon Street Capital LLC boosted its position in shares of Assembly Biosciences by 352.6% during the 2nd quarter. Lyon Street Capital LLC now owns 136,200 shares of the biopharmaceutical company’s stock valued at $2,813,000 after acquiring an additional 106,107 shares in the last quarter. Institutional investors own 72.41% of the company’s stock.
Several analysts have issued reports on the stock. BidaskClub upgraded shares of Assembly Biosciences from a “strong sell” rating to a “sell” rating in a research report on Thursday, August 3rd. Zacks Investment Research lowered shares of Assembly Biosciences from a “hold” rating to a “sell” rating in a research report on Monday, August 14th. Finally, Chardan Capital restated a “buy” rating on shares of Assembly Biosciences in a research report on Sunday, September 17th.
Assembly Biosciences Company Profile
Assembly Biosciences, Inc is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome.
Receive News & Ratings for Assembly Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.